Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
AntlerA Therapeutics, Inc. (United States)
Alternate names:
AntlerA,
AntlerA Therapeutics,
AntlerA Therapeutics, Inc.
ROR:
03bk4a791
OpenAlex ID:
I4405260167
Targeted alveolar regeneration with Frizzled-specific agonists
2023
·
Ahmad N. Nabhan
, Joshua D. Webster
, et al.
·
Cell
·
87
PDF
A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy
2021
·
Rony Chidiac
, Md. Abedin
, et al.
·
EMBO Molecular Medicine
·
75
C1q limits cystoid edema by maintaining basal β-catenin–dependent signaling and blood-retina barrier function
2025
·
Lingling Zhang
, Jacklyn Levey
, et al.
·
JCI Insight
·
4
A FZD4/LRP5 agonist restores pericyte coverage and vascular integrity by increasing PDGFB signaling
2026
·
Jacklyn Levey
, Miranda Howe
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
Abstract P3-08-04: Discovery of cancer genes and pathways operative in PI3K-activated mammary cancer reveals clinically relevant genotype-phenotype correlations
2023
·
Morito Kurata
, Emiily Pope
, et al.
·
Cancer Research
A PanFzd receptor agonist induces β‐catenin activation to promote hepatic repair after surgical and acetaminophen‐induced injury
2022
·
Shikai Hu
, Sucha Singh
, et al.
·
The FASEB Journal
Show more works
View as search
Works count:
6
Citation count:
815
Year
Topic
Type